

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 35 of 35 returned.**

-
- ☐ 1. [20030055006](#). 25 Jun 01. 20 Mar 03. Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use. Siemeister, Gerhard, et al. 514/21; A61K038/18.
-
- ☐ 2. [20030008840](#). 07 May 02. 09 Jan 03. Methods for treating cancer. Vicari, Alain P., et al. 514/44; 424/144.1 424/178.1 424/93.2 A61K048/00 A61K039/395.
-
- ☐ 3. [20020197700](#). 30 Aug 01. 26 Dec 02. Receptor of the **EDb-fibronectin domains**. Menrad, Andreas, et al. 435/226; 435/320.1 435/325 435/69.1 435/7.23 536/23.2 G01N033/574 C07H021/04 C12N009/64 C12P021/02 C12N005/06.
-
- ☐ 4. [7335775](#). 25 Aug 06; 26 Feb 08. Effector conjugates, process for their production and their pharmaceutical use. Berger, Markus, et al. 546/268.1; 548/146 548/206 548/215 549/357. C07D277/20 20060101 C07D417/08 20060101 .
-
- ☐ 5. [WO2007128557A1](#). 26 Apr 07. 15 Nov 07. COMBINATION OF AN ANTI **EDB FIBRONECTIN DOMAIN** ANTIBODY L19-SIP AND AN ANTI-EGFR ANTIBODY. SIEGER, STEPHANIE, et al. C07K016/18;.
-
- ☐ 6. [EP001842553A1](#). 07 Apr 06. 10 Oct 07. Combination of an anti-**EDb fibronectin domain** antibody/IL2 fusion protein and a further small molecule. MENRAD, ANDREAS DR, et al. C07K016/18;.
-
- ☐ 7. [WO2007054120A1](#). 09 Nov 05. 18 May 07. IDENTIFICATION AND CHARACTERIZATION OF FUNCTION-BLOCKING ANTI-ED-B-FIBRONECTIN ANTIBODIES. MENRAD, ANDREAS, et al.
-
- ☐ 8. [EP001663320A1](#). 01 Sep 04. 07 Jun 06. TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY L19 AGAINST **FIBRONECTIN ED-B**. BORSI, LAURA, et al. A61K051/10; A61P035/00.
-
- ☐ 9. [DE102004050101A1](#). 14 Oct 04. 20 Apr 06. Recombined polypeptide antibody or antibody fragment binds the **ED-B domain of Fibronectin**. PRASSLER, JOSEF, et al. C07K016/18;.
-
- ☐ 10. [WO2005023318A1](#). 01 Sep 04. 17 Mar 05. TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY L19 AGAINST **FIBRONECTIN ED-B**. BORSI, LAURA, et al. A61K051/10; A61P035/00.
-
- ☐ 11. [EP001514561A1](#). 10 Sep 03. 16 Mar 05. Targeting of tumor vasculature using radiolabelled antibody L19 against **fibronectin ED-B**. A61K051/10;.
-
- ☐ 12. [WO003076469A2](#). 11 Mar 03. 18 Sep 03. SELECTIVE TARGETING OF TUMOR VASCULATURE USING ANTIBODY MOLECULES. BORSI, LAURA, et al. C07K016/00;.
-
- ☐ 13. [DE10123133A1](#). 02 May 01. 28 Nov 02. New proteins binding specifically to the **ED-b fibronectin domain**, are cell adhesion and proliferation mediators useful e.g. in screening tests.
-

MENRAD, ANDREAS, et al. C07K014/435; C07K016/00 C12N005/10 C12N015/12 A61K038/17 C12Q001/68.

14. DE010945803A1. 07 Sep 00. 11 Apr 02. New proteins binding specifically to the **ED-b fibronectin domain**, are cell adhesion and proliferation mediators useful e.g. in screening tests. MENRAD, ANDREAS, et al. C07K014/435; C07K016/00 A61K038/17 C12N005/16.

15. WO 2009056240 A1. Determining the activity of a molecule comprises incubating the molecule with the target which is covalently or non-covalently bound to a surface and the target is not bound to the surface via cells expressing the target on the cell surface. BARBIN K, et al.

16. EP 2036576 A1. Stratifying a tumor cell or tumor tissue, comprises contacting an extra domain B (ED-B) fibronectin-specific molecule with a tumor cell or tissue and assessing the binding of the ED-B fibronectin-specific molecule, and stratifying. BERNDORFF D, et al.

17. WO 2008052679 A2. Use of fusion protein comprising a targeting part that recognizes extra domain B (ED-B) fibronectin and an effector part is a cytokine for manufacturing a medicament for treating and preventing atherosclerosis. GRAF K, et al.

18. NZ 544443 A. Missing claims; abstract and indexing based on disclosure. Patent Office notified - New antibodies or antibody fragments that bind the **ED-B domain of fibronectin** and block its function, useful for diagnostic applications.

19. WO 2007128557 A1. New combination comprising at least a fusion protein and an anti-epidermal growth factor receptor (EGFR) antibody, useful in manufacturing a medicament for treating cancer, preferably pancreatic cancer. BERNDORFF D, et al.

20. WO 2007115837 A2. Use of a fusion protein comprising an antibody part, specifically recognizing the **ED-B-fibronectin** domain and an interleukin-2 part for manufacturing a medicament for treating pancreatic cancer. MENRAD A, et al.

21. EP 1842553 A1. Use of anti-extra domain B of fibronectin/interleukin-2 fusion protein, for treating pancreatic cancer. MENRAD A, et al.

22. AU 2006201095 A1. New polypeptide that binds specifically to the **ED-B domain of fibronectin** and inhibits interaction between the **ED-B domain** and its receptor, useful for diagnosing, preventing, or treating hyperproliferative diseases, e.g. cancer.

23. DE 102004050101 A1. Recombined polypeptide antibody or antibody fragment binds the **ED-B domain of Fibronectin**. MENRAD A, et al.

24. EP 1619501 A1. Use of conjugate of cyanine dyes with angiogenesis specific binding component, for production of diagnostic for diagnosis of micrometastasis or small proliferative lesions, such as precancerosis, dysplasia, metaplasia, endometriosis. HAUFF P, et al.

25. WO 2005074901 A2. New effector conjugate of specific formula, as uniform isomer/mixture of different isomers and/or as their salt, for use as medication for treating diseases that are associated with proliferative processes, or disease consisting e.g. tumors. BOSSLET K, et al.

26. WO 2005037312 A2. Detection of atherosclerotic plaques, using binding molecules specific for the extra-B domain of fibronectin, also useful for preventing, e.g. cardiac infarction and angina

pectoris. HELDMANN D.

- ☐ 27. WO 2005023318 A1. Specific binding component that binds human **ED-B**, labeled with isotope and comprising antigen-binding site that comprises antibody VH and VL **domain**, useful in manufacture of medicament for treating lesion of angiogenesis or tumor. BALZA E, et al.
- ☐ 28. EP 1514561 A1. New isotopically labeled specific binding member that binds human **ED-B**, useful for manufacturing a medicament for treating a lesion of pathological angiogenesis, tumor, or for manufacturing a diagnostic reagent. BALZA E, et al.
- ☐ 29. WO 2005005985 A1. Device for direct, quantitative determination of analytes, useful for diagnosis, comprises immobilized specific binding agent, labeled analyte conjugate and immobilized binding agent for the label. LICHA K, et al.
- ☐ 30. EP 1462119 A1. Producing pharmaceutical that modulates megalin-receptor mediated binding and/or uptake of radiodiagnostic and/or radiotherapeutic, in kidney cells of patients. BRAEUTIGAM M, et al.
- ☐ 31. WO 2004065491 A1. New indotricarbocyanine dyes are conjugated to biomolecules, used in fluorescence diagnosis of e.g. tumors. KAI L, et al.
- ☐ 32. WO 2004050089 A1. New epithilone derivatives are useful for the treatment of diseases associated with proliferative diseases e.g. tumor diseases, inflammatory diseases and neurodegenerative diseases. BOSSLET K, et al.
- ☐ 33. WO 03076469 A2. New specific binding member that binds human **ED-B** and comprises an antigen-binding site consisting of antibody VH and VL **domains**, useful for preparing a composition for treating tumors or a lesion of pathological angiogenesis. BALZA E, et al.
- ☐ 34. DE 10104389 A1. New multimeric photosensitizer, useful in photodynamic therapy of cancers and other angiogenic conditions, can also be conjugated with e.g. protein, antibody or oligonucleotide. HACKBARTH S, et al.
- ☐ 35. WO 0220563 A2. New proteins binding specifically to the **ED-b fibronectin domain**, are cell adhesion and proliferation mediators useful e.g. in screening tests. BAHR I, et al.

Generate Collection

Print

Term	Documents
(21 NOT 19 NOT 14).PGPB,USPT,USOC,EPAB,JPAB,DWPL	35
(L21 not L19 not L14).PGPB,USPT,USOC,EPAB,JPAB,DWPL	35

Prev Page Next Page Go to Doc#